{
  "fetchedAt": "2026-09-28T15:54:21.719Z",
  "source": "https://clinicaltrials.gov/data-api/api",
  "note": "Verbatim registry facts from ClinicalTrials.gov, generated by scripts/fetch-trials.mjs. Editorial status/phase labels live in the candidate content files and may differ (see CLAUDE.md §7).",
  "studies": {
    "NCT07330440": {
      "nctId": "NCT07330440",
      "briefTitle": "A Phase I Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) Post-Vaccination",
      "officialTitle": "A Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of an mRNA Vaccine Against Herpes Simplex Virus Type 2 (HSV-2) in Healthy Participants Aged 18-55 Years, Stratified by Serostatus",
      "overallStatus": "ENROLLING_BY_INVITATION",
      "statusLabel": "Enrolling by invitation",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 144,
      "enrollmentType": "ESTIMATED",
      "leadSponsor": "Changchun BCHT Biotechnology Co.",
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Low-Dose Cohort"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Mid-Dose Cohort"
        },
        {
          "type": "BIOLOGICAL",
          "name": "High-Dose Cohort"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo Group"
        }
      ],
      "startDate": "2025-10-13",
      "primaryCompletionDate": "2027-03-04",
      "completionDate": "2027-06",
      "lastUpdatePostDate": "2026-01-09",
      "studyUrl": "https://clinicaltrials.gov/study/NCT07330440",
      "error": null,
      "candidates": [
        "BCHT HSV-2 mRNA vaccine"
      ],
      "candidateSlugs": [
        "bcht-hsv-2-mrna"
      ]
    },
    "NCT05432583": {
      "nctId": "NCT05432583",
      "briefTitle": "A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions",
      "officialTitle": "Phase I, Randomized, Observer-blinded, 3-part, Dose Escalation and Expanded Safety and Dose Evaluation Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Prophylactic Vaccine for the Prevention of Genital Lesions Caused by Herpes Simplex Virus (HSV)-2 and Potentially HSV-1",
      "overallStatus": "ACTIVE_NOT_RECRUITING",
      "statusLabel": "Active, not recruiting",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 318,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "BioNTech SE",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "BNT163"
        },
        {
          "type": "OTHER",
          "name": "Placebo"
        }
      ],
      "startDate": "2022-12-08",
      "primaryCompletionDate": "2026-10",
      "completionDate": "2026-10",
      "lastUpdatePostDate": "2025-10-20",
      "studyUrl": "https://clinicaltrials.gov/study/NCT05432583",
      "error": null,
      "candidates": [
        "BNT163"
      ],
      "candidateSlugs": [
        "bnt163"
      ]
    },
    "NCT04222985": {
      "nctId": "NCT04222985",
      "briefTitle": "Safety and Efficacy of 4 Investigational HSV 2 Vaccines in Adults With Recurrent Genital Herpes Caused by HSV 2",
      "officialTitle": "Safety and Efficacy of 4 Investigational HSV 2 Vaccines Administered by Intramuscular Route in Adults With Recurrent Genital Herpes Caused by HSV 2",
      "overallStatus": "TERMINATED",
      "statusLabel": "Terminated",
      "whyStopped": "business reasons-Phase 2/Part B not conducted. Study terminated after last patient enrolled in Phase 1/Part A",
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 24,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Sanofi Pasteur, a Sanofi Company",
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 1"
        },
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 2"
        },
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 3"
        },
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 4"
        },
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 5"
        },
        {
          "type": "BIOLOGICAL",
          "name": "HSV 2 Formulation 6"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Sodium Chloride 0.9%"
        }
      ],
      "startDate": "2020-02-18",
      "primaryCompletionDate": "2021-05-19",
      "completionDate": "2021-05-19",
      "lastUpdatePostDate": "2022-10-25",
      "studyUrl": "https://clinicaltrials.gov/study/NCT04222985",
      "error": null,
      "candidates": [
        "G103",
        "HSV529"
      ],
      "candidateSlugs": [
        "g103",
        "hsv529"
      ]
    },
    "NCT01667341": {
      "nctId": "NCT01667341",
      "briefTitle": "Safety and Immunogenicity Study of Therapeutic HSV-2 Vaccine",
      "officialTitle": "A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "phaseLabel": "phase 1/2",
      "enrollmentCount": 143,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Genocea Biosciences, Inc.",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003 with Matrix M-2"
        },
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo"
        }
      ],
      "startDate": "2012-07",
      "primaryCompletionDate": "2014-05-09",
      "completionDate": "2014-05-09",
      "lastUpdatePostDate": "2018-06-01",
      "studyUrl": "https://clinicaltrials.gov/study/NCT01667341",
      "error": null,
      "candidates": [
        "GEN-003"
      ],
      "candidateSlugs": [
        "gen-003"
      ]
    },
    "NCT02114060": {
      "nctId": "NCT02114060",
      "briefTitle": "Dose Ranging Safety and Efficacy of Therapeutic HSV-2 Vaccine",
      "officialTitle": "A Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Varying Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2 Infection",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 310,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Genocea Biosciences, Inc.",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003 Vaccine (30μg of each antigen)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003 Vaccine (60μg of each antigen)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (25μg)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (50μg)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (75μg)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Placebo"
        }
      ],
      "startDate": "2014-07",
      "primaryCompletionDate": "2016-02",
      "completionDate": "2016-02",
      "lastUpdatePostDate": "2017-10-16",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02114060",
      "error": null,
      "candidates": [
        "GEN-003"
      ],
      "candidateSlugs": [
        "gen-003"
      ]
    },
    "NCT02300142": {
      "nctId": "NCT02300142",
      "briefTitle": "Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 Study",
      "officialTitle": "Rollover Trial for Placebo Subjects Previously Enrolled Into GEN-003-002 - Randomized, Double-Blind, Factorial Study to Compare the Safety and Efficacy of Combinations of GEN-003 and Matrix-M2 in Subjects With Genital HSV-2",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 37,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Genocea Biosciences, Inc.",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003 Vaccine (30μg of each antigen)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003 Vaccine (60μg of each antigen)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (25μg)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (50μg)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2 Adjuvant (75μg)"
        }
      ],
      "startDate": "2015-01",
      "primaryCompletionDate": "2016-06",
      "completionDate": "2016-06",
      "lastUpdatePostDate": "2017-10-16",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02300142",
      "error": null,
      "candidates": [
        "GEN-003"
      ],
      "candidateSlugs": [
        "gen-003"
      ]
    },
    "NCT02515175": {
      "nctId": "NCT02515175",
      "briefTitle": "Evaluating New Formulation of Therapeutic HSV-2 Vaccine",
      "officialTitle": "A Randomized, Double-Blind Study to Evaluate a New Formulation of GEN-003 in Subjects With Genital HSV-2 Infection",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 131,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Genocea Biosciences, Inc.",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2"
        },
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003"
        },
        {
          "type": "DRUG",
          "name": "Placebo"
        }
      ],
      "startDate": "2015-11",
      "primaryCompletionDate": "2016-07",
      "completionDate": "2017-05-25",
      "lastUpdatePostDate": "2018-05-22",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02515175",
      "error": null,
      "candidates": [
        "GEN-003"
      ],
      "candidateSlugs": [
        "gen-003"
      ]
    },
    "NCT03146403": {
      "nctId": "NCT03146403",
      "briefTitle": "Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection",
      "officialTitle": "A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection",
      "overallStatus": "TERMINATED",
      "statusLabel": "Terminated",
      "whyStopped": "2017 business decision to cease GEN-003 spending.",
      "hasResults": true,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 33,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Genocea Biosciences, Inc.",
      "conditions": [
        "Genital Herpes",
        "HSV-2 Infection"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "GEN-003"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Matrix-M2"
        },
        {
          "type": "OTHER",
          "name": "0.9% normal saline"
        }
      ],
      "startDate": "2017-05-24",
      "primaryCompletionDate": "2017-12-22",
      "completionDate": "2018-06-11",
      "lastUpdatePostDate": "2019-02-19",
      "studyUrl": "https://clinicaltrials.gov/study/NCT03146403",
      "error": null,
      "candidates": [
        "GEN-003"
      ],
      "candidateSlugs": [
        "gen-003"
      ]
    },
    "NCT04762511": {
      "nctId": "NCT04762511",
      "briefTitle": "A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years",
      "officialTitle": "A Phase I, Single-blind, Randomised, Placebo-controlled, Dose Escalation Study to Evaluate the Reactogenicity, Safety and Immune Response of an HSV Vaccine in Healthy Participants Aged 18-40 Years",
      "overallStatus": "TERMINATED",
      "statusLabel": "Terminated",
      "whyStopped": "To enable development of an enhanced version of the vaccine",
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 17,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "GlaxoSmithKline",
      "conditions": [
        "Herpes Simplex"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "Lower dose formulation of HSV vaccine (GSK4108771A)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Low dose formulation of HSV vaccine (GSK4108771A)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Medium dose formulation of HSV vaccine (GSK4108771A)"
        },
        {
          "type": "BIOLOGICAL",
          "name": "High dose formulation of HSV vaccine (GSK4108771A)"
        },
        {
          "type": "DRUG",
          "name": "Placebo (saline)"
        }
      ],
      "startDate": "2021-03-02",
      "primaryCompletionDate": "2021-05-26",
      "completionDate": "2021-05-26",
      "lastUpdatePostDate": "2021-06-28",
      "studyUrl": "https://clinicaltrials.gov/study/NCT04762511",
      "error": null,
      "candidates": [
        "GSK4108771A"
      ],
      "candidateSlugs": [
        "gsk4108771a"
      ]
    },
    "NCT00057330": {
      "nctId": "NCT00057330",
      "briefTitle": "HerpeVac Trial for Young Women",
      "officialTitle": "A Double-Blind, Randomized, Controlled Phase III Study to Assess the Prophylactic Efficacy and Safety of gD-Alum/MPL Vaccine in the Prevention of Genital Herpes Disease in Young Women Who Are HSV-1 and -2 Seronegative",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": true,
      "phases": [
        "PHASE3"
      ],
      "phaseLabel": "phase 3",
      "enrollmentCount": 8323,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "GlaxoSmithKline",
      "conditions": [
        "Herpes Simplex Infection"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine"
        },
        {
          "type": "BIOLOGICAL",
          "name": "Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine"
        }
      ],
      "startDate": "2003-01-14",
      "primaryCompletionDate": "2009-08-22",
      "completionDate": "2009-08-22",
      "lastUpdatePostDate": "2018-08-27",
      "studyUrl": "https://clinicaltrials.gov/study/NCT00057330",
      "error": null,
      "candidates": [
        "Herpevac (gD2 subunit, GSK)"
      ],
      "candidateSlugs": [
        "herpevac-gd2-gsk"
      ]
    },
    "NCT01687595": {
      "nctId": "NCT01687595",
      "briefTitle": "Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes",
      "officialTitle": "A Phase 2a, Multicenter, Double-blinded, Randomized, 2-Period Trial to Evaluate the Effect of HerpV Administered in Combination With the Stimulon® Adjuvant QS-21 on Viral Shedding in Adults With Recurrent Genital Herpes",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": true,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 80,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Agenus Inc.",
      "conditions": [
        "Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "HerpV and QS-21"
        },
        {
          "type": "DRUG",
          "name": "Placebo"
        }
      ],
      "startDate": "2012-10-29",
      "primaryCompletionDate": "2013-09",
      "completionDate": "2015-01",
      "lastUpdatePostDate": "2021-07-13",
      "studyUrl": "https://clinicaltrials.gov/study/NCT01687595",
      "error": null,
      "candidates": [
        "HerpV"
      ],
      "candidateSlugs": [
        "herpv"
      ]
    },
    "NCT01915212": {
      "nctId": "NCT01915212",
      "briefTitle": "Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection",
      "officialTitle": "Phase I Study of the Safety of a Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 69,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "HSV529"
        },
        {
          "type": "OTHER",
          "name": "Placebo"
        }
      ],
      "startDate": "2013-09-26",
      "primaryCompletionDate": "2017-03-06",
      "completionDate": "2017-03-06",
      "lastUpdatePostDate": "2026-09-01",
      "studyUrl": "https://clinicaltrials.gov/study/NCT01915212",
      "error": null,
      "candidates": [
        "HSV529"
      ],
      "candidateSlugs": [
        "hsv529"
      ]
    },
    "NCT02571166": {
      "nctId": "NCT02571166",
      "briefTitle": "HSV529 Vaccine in HSV-2 Seropositive Adults",
      "officialTitle": "Phase I Study of the Genital Immune Response to Live, Attenuated HSV529 Vaccine in HSV-2 Seropositive Adults",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 10,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Fred Hutchinson Cancer Center",
      "conditions": [
        "Herpes Simplex Virus 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "HSV529"
        },
        {
          "type": "DRUG",
          "name": "Valacyclovir"
        }
      ],
      "startDate": "2015-11",
      "primaryCompletionDate": "2018-12-01",
      "completionDate": "2018-12-01",
      "lastUpdatePostDate": "2019-01-14",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02571166",
      "error": null,
      "candidates": [
        "HSV529"
      ],
      "candidateSlugs": [
        "hsv529"
      ]
    },
    "NCT06033261": {
      "nctId": "NCT06033261",
      "briefTitle": "A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes",
      "officialTitle": "A Phase 1/2, Randomized, Observer-Blind, Controlled, Dose-Ranging Study of mRNA-1608, an HSV-2 Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": true,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "phaseLabel": "phase 1/2",
      "enrollmentCount": 303,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "ModernaTX, Inc.",
      "conditions": [
        "Genital Herpes"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "mRNA-1608"
        },
        {
          "type": "BIOLOGICAL",
          "name": "BEXSERO"
        }
      ],
      "startDate": "2023-09-06",
      "primaryCompletionDate": "2025-04-25",
      "completionDate": "2025-04-25",
      "lastUpdatePostDate": "2026-05-08",
      "studyUrl": "https://clinicaltrials.gov/study/NCT06033261",
      "error": null,
      "candidates": [
        "mRNA-1608"
      ],
      "candidateSlugs": [
        "mrna-1608"
      ]
    },
    "NCT00274300": {
      "nctId": "NCT00274300",
      "briefTitle": "Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2",
      "officialTitle": "A Phase I, Two-Center, Open-Label, Dose-Escalating Study to Investigate the Safety, Tolerability and Immunogenicity of pPJV7630, a Therapeutic DNA Vaccine for Herpes Simplex Virus Type 2 (HSV-2), in Patients With Recurrent Genital Herpes Caused by HSV-2",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 36,
      "enrollmentType": null,
      "leadSponsor": "PowderMed",
      "conditions": [
        "HSV-2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "pPJV7630 administered by PMED"
        }
      ],
      "startDate": "2004-08",
      "primaryCompletionDate": null,
      "completionDate": "2005-07",
      "lastUpdatePostDate": "2007-01-29",
      "studyUrl": "https://clinicaltrials.gov/study/NCT00274300",
      "error": null,
      "candidates": [
        "pPJV7630"
      ],
      "candidateSlugs": [
        "ppjv7630"
      ]
    },
    "NCT00310271": {
      "nctId": "NCT00310271",
      "briefTitle": "A Safety Study to Assess a DNA Vaccine Administered by Particle Mediated Delivery to the Skin in Healthy Subjects",
      "officialTitle": "A Phase I Study Assessing Safety and Tolerability of a DNA Vaccine With a DNA Encoded Immunostimulator , Administered by Particle Mediated Epidermal Delivery Using the PowderMed ND10 Delivery System in HSV-2 Seronegative Healthy Volunteers",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1"
      ],
      "phaseLabel": "phase 1",
      "enrollmentCount": 42,
      "enrollmentType": null,
      "leadSponsor": "PowderMed",
      "conditions": [
        "HSV-2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "pPJV7630 with pPJV2012 administered by PMED"
        }
      ],
      "startDate": "2006-04",
      "primaryCompletionDate": null,
      "completionDate": "2006-12",
      "lastUpdatePostDate": "2008-11-21",
      "studyUrl": "https://clinicaltrials.gov/study/NCT00310271",
      "error": null,
      "candidates": [
        "pPJV7630"
      ],
      "candidateSlugs": [
        "ppjv7630"
      ]
    },
    "NCT02030301": {
      "nctId": "NCT02030301",
      "briefTitle": "Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in Adults",
      "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation, Phase 1/2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 Therapeutic DNA Vaccines in Symptomatic HSV-2-Seropositive Adults",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "phaseLabel": "phase 1/2",
      "enrollmentCount": 165,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Vical",
      "conditions": [
        "Genital Herpes Simplex Type 2"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "VCL-HB01"
        },
        {
          "type": "BIOLOGICAL",
          "name": "VCL-HM01"
        },
        {
          "type": "BIOLOGICAL",
          "name": "PBS"
        }
      ],
      "startDate": "2013-12",
      "primaryCompletionDate": "2015-06",
      "completionDate": "2016-02",
      "lastUpdatePostDate": "2019-02-27",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02030301",
      "error": null,
      "candidates": [
        "VCL-HB01"
      ],
      "candidateSlugs": [
        "vcl-hb01"
      ]
    },
    "NCT02837575": {
      "nctId": "NCT02837575",
      "briefTitle": "Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine",
      "officialTitle": "A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection",
      "overallStatus": "COMPLETED",
      "statusLabel": "Completed",
      "whyStopped": null,
      "hasResults": false,
      "phases": [
        "PHASE2"
      ],
      "phaseLabel": "phase 2",
      "enrollmentCount": 261,
      "enrollmentType": "ACTUAL",
      "leadSponsor": "Vical",
      "conditions": [
        "Herpes Genitalis"
      ],
      "interventions": [
        {
          "type": "BIOLOGICAL",
          "name": "VCL-HB01"
        },
        {
          "type": "OTHER",
          "name": "Phosphate-buffered saline"
        }
      ],
      "startDate": "2016-09",
      "primaryCompletionDate": "2018-04",
      "completionDate": "2018-12",
      "lastUpdatePostDate": "2019-02-27",
      "studyUrl": "https://clinicaltrials.gov/study/NCT02837575",
      "error": null,
      "candidates": [
        "VCL-HB01"
      ],
      "candidateSlugs": [
        "vcl-hb01"
      ]
    }
  }
}